Skudexa combines the effects of tramadol, a centrally acting synthetic opioid analgesic with those of the non-opioid analgesic dexketoprofen, an established NSAID.
The novel combination is licensed for the short-term treatment of moderate to severe acute pain in adults whose pain is considered sufficient to warrant use of the two analgesics concurrently.
The recommended dose is one tablet (tramadol 75mg/dexketoprofen 25mg) taken as needed, with a minimum dosing interval of eight hours, up to a maximum of three tablets daily. The duration of treatment should be limited to the symptomatic period and should not exceed five days.
In elderly patients an initial daily maximum dose of two tablets should be observed. Once good general tolerance has been ascertained the maximum daily dose can be increased to three tablets daily.
Skudexa is not recommended for use in children or adolescents due to an absence of safety and efficacy data relating to these populations. The product is contraindicated for use in women who are pregnant or breastfeeding.